NCT04796402 (B-EPIC) is a Phase 4 clinical trial of Bamlanivimab in Covid19, sponsored by Fraser Health.

Who is sponsoring NCT04796402?

NCT04796402 is sponsored by Fraser Health.

What drugs are being tested in NCT04796402?

Interventions in NCT04796402: Bamlanivimab, Standard of Care.

Is NCT04796402 still recruiting?

NCT04796402 is currently status unknown. Last updated 26 August 2021.

Last reviewed 2021-08-26 · How we verify

NCT04796402: B-EPIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19

Status unknown Phase 4 Last updated 26 August 2021

What this trial tests

Phase 4 trial testing Bamlanivimab in Covid19 in 576 participants. Status unknown.

Timeline

17 March 2021

Primary endpoint
7 June 2021

31 December 2021

Quick facts

Lead sponsor	Fraser Health
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	576
Start date	17 March 2021
Primary completion	7 June 2021
Estimated completion	31 December 2021
Sites	1 location across Canada

Drugs / interventions tested

Bamlanivimab (BAMLANIVIMAB) — full drug profile →
Standard of Care

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Fraser Health — full company profile →

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to test whether a new medication called bamlanivimab is safe and effective at reducing the need for hospitalization due to COVID-19.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, et al · · 2021 · cited 126× · PMID 34473343 · DOI 10.1002/14651858.cd013825.pub2
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Zhang J, Zhang H, Sun L. · · 2022 · cited 21× · PMID 35220888 · DOI 10.1080/19420862.2022.2031483
Keeping up with the COVID's-Could siRNA-based antivirals be a part of the answer?
Forgham H, Kakinen A, Qiao R, Davis TP. · · 2022 · cited 16× · PMID 35941991 · DOI 10.1002/exp.20220012
Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective.
Bhattacharya M, Chatterjee S, Mallik B, Sharma AR, et al · · 2022 · cited 12× · PMID 36298477 · DOI 10.3390/vaccines10101612
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future.
Tuccori M, Convertino I, Ferraro S, Valdiserra G, et al · · 2021 · cited 11× · PMID 34304682 · DOI 10.1080/17460441.2021.1960819
An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies.
Chatterjee S, Choudhury S, Das D. · · 2022 · cited 4× · PMID 35343208 · DOI 10.4103/ijp.ijp_519_21
Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19*
Mohamed N, Hamad M, Ghaleb A, Esmat G, et al · · 2022

Verify or expand the search:

Other trials of Bamlanivimab

Trials testing the same drug.

NCT05268601 — COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2 · completed
NCT04701658 — A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) · Phase 2 · completed
NCT04634409 — A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness · Phase 2 · completed
NCT04497987 — A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Ho · Phase 3 · completed
NCT04603651 — Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19 · no longer available

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Fraser Health trials

Trials by the same sponsor.

NCT07437703 — Labour Pain Relief Options: Video Versus Pamphlet for Easing Fear of Birth and Improving Preparedness in Pregnant Patien · NA · not yet recruiting
NCT06856161 — A Novel Blood Test as a Biomarker in Mental Health · recruiting
NCT06867458 — Steriwave ICU Pilot Study · NA · completed
NCT05824338 — Testing the Feasibility of Using Ropivacaine in Spinal Anesthesia for Patients With Lower Back Surgery · EARLY_PHASE1 · recruiting
NCT06019078 — pEEG Monitoring Effect on Delirium, Ventilator Days, and PICS · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04796402 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fraser Health
Last refreshed: 26 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04796402.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing